David A. Giljohann

Chief Executive Officer at Exicure Operating Co.

David A. Giljohann

David A. Giljohann

Chief Executive Officer at Exicure Operating Co.

Biography

David A. Giljohann
Chief Executive Officer

Dr. Giljohann is our Chief Executive Officer and director. Dr. Giljohann has served as our CEO since November 2013 and has been on our board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was our Chief Operating Officer. From 2011 until June 2012, Dr. Giljohann served as our principal scientist. Dr. Giljohann was our founding scientist in 2011. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC, our largest stockholder, in 2009.

Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™ and Spherical Nucleic Acid (SNA™) technologies. Dr. Giljohann was named to the Endpoint News’ “Under 40s” biopharma executives list in 2018 and the Analytical Scientist’s “Top 40 Under 40 Power List” in 2014. Dr. Giljohann has also been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition.

Dr. Giljohann received his B.A. in Biology and Ph.D. in Biochemistry from Northwestern University.

Overview
Career Highlights

Exicure Operating Co.
Exicure, Inc.

RelSci Relationships

405

Number of Boards

2

Birthday

1981

Age

39

Relationships
RelSci Relationships are individuals David A. Giljohann likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Business Officer at NGM Biopharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Quanterix Corp.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Angion Biomedica Corp.

Relationship likelihood: Strong

Co-Founder at Exicure, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Exicure Operating Co.

Relationship likelihood: Strong

Chief Operating Officer at Exicure Operating Co.

Relationship likelihood: Strong

Vice President, Head of Business Development at Exicure Operating Co.

Relationship likelihood: Strong

Assistant Professor at Northwestern University

Relationship likelihood: Strong

Chairman of the Board, President, Chief Executive Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Senior Vice President & Chief Commercial Officer at Assertio Therapeutics, Inc.

Relationship likelihood: Strong

Paths to David A. Giljohann
Potential Connections via
Relationship Science
You
David A. Giljohann
Chief Executive Officer at Exicure Operating Co.
Education

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. In 1853 the founders purchased a 379-acre tract of land on the shore of Lake Michigan 12 miles north of Chicago. They established a campus and developed the land near it, naming the surrounding town Evanston in honor of one of the University's founders, John Evans. After completing its first building, its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Northwestern has three campuses and a total of 12 Schools and Colleges (one of which is located in South Florida. Two campuses are located on Lake Michigan, a 240-acre campus in Evanston, the first suburb north of Chicago, and a 25-acre campus in Chicago. One campus is located in Doha, Qatar. Northwestern University combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. It provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

Career History
Chief Executive Officer
Current

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Director & Chief Executive Officer
2011 - Current

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Principal Scientist
Prior
Transactions
Details Hidden

Exicure Operating Co. raised money in a private placement transaction

Details Hidden

Exicure Operating Co. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations

David A. Giljohann is affiliated with Exicure Operating Co., Exicure, Inc., Aurasense LLC

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David A. Giljohann. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David A. Giljohann's profile does not indicate a business or promotional relationship of any kind between RelSci and David A. Giljohann.